AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
etidronic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| calcium metabolism regulator, pharmaceutical aid | 1098 | 2809-21-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.40 | g | O |
| 1.50 | g | P |
| 0.40 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 50 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 97.07 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 5 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,JAK3,MAP2K6,MAP3K14,MAP3K2,MAP3K21,MAP3K7,MAP4K1,MAPK10,MAPK7,MAPK9,NTRK1,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CD,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 | 55 | |||
| kinase-selectivity-class | ACVR2B,AURKA,AXL,BMX,BRAF,CDK4,CDK9,DDR1,DYRK1B,EPHB4,ERBB2,GRK2,JAK2,MAP2K6,MAP3K14,MAPK7,PIK3CD,PIK3CG,PRKDC,STK33,SYK,TEK,TGFBR1,ZAP70 | 24 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 1, 1977 | FDA | PROCTER AND GAMBLE |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Venous pressure jugular increased | 105.72 | 62.47 | 17 | 1874 | 583 | 90625973 |
| Carbuncle | 103.72 | 62.47 | 19 | 1872 | 1417 | 90625139 |
| Monoclonal immunoglobulin present | 96.30 | 62.47 | 19 | 1872 | 2105 | 90624451 |
| Kyphosis | 96.13 | 62.47 | 20 | 1871 | 2888 | 90623668 |
| Hypothalamo-pituitary disorder | 95.19 | 62.47 | 19 | 1872 | 2233 | 90624323 |
| Wrist deformity | 88.31 | 62.47 | 19 | 1872 | 3219 | 90623337 |
| Body height decreased | 86.01 | 62.47 | 24 | 1867 | 11925 | 90614631 |
| Atypical femur fracture | 85.40 | 62.47 | 21 | 1870 | 6400 | 90620156 |
| Osteoporosis | 84.97 | 62.47 | 41 | 1850 | 96490 | 90530066 |
| Rectal prolapse | 83.16 | 62.47 | 17 | 1874 | 2250 | 90624306 |
| Hepatic steatosis | 77.18 | 62.47 | 29 | 1862 | 36916 | 90589640 |
| Overweight | 76.85 | 62.47 | 19 | 1872 | 5915 | 90620641 |
| Fibrosis | 76.80 | 62.47 | 19 | 1872 | 5933 | 90620623 |
| Bundle branch block left | 71.49 | 62.47 | 19 | 1872 | 7866 | 90618690 |
| Dyslipidaemia | 71.36 | 62.47 | 20 | 1871 | 10087 | 90616469 |
| Nephropathy | 68.52 | 62.47 | 19 | 1872 | 9216 | 90617340 |
| Arthritis | 63.86 | 62.47 | 41 | 1850 | 167274 | 90459282 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Carbuncle | 106.73 | 61.48 | 19 | 1908 | 1448 | 110585924 |
| Atypical femur fracture | 105.86 | 61.48 | 24 | 1903 | 6195 | 110581177 |
| Osteoporosis | 99.38 | 61.48 | 42 | 1885 | 87110 | 110500262 |
| Monoclonal immunoglobulin present | 96.32 | 61.48 | 19 | 1908 | 2521 | 110584851 |
| Venous pressure jugular increased | 94.98 | 61.48 | 17 | 1910 | 1335 | 110586037 |
| Hypothalamo-pituitary disorder | 94.16 | 61.48 | 19 | 1908 | 2827 | 110584545 |
| Kyphosis | 92.02 | 61.48 | 19 | 1908 | 3168 | 110584204 |
| Wrist deformity | 92.01 | 61.48 | 19 | 1908 | 3170 | 110584202 |
| Rectal prolapse | 84.13 | 61.48 | 17 | 1910 | 2546 | 110584826 |
| Body height decreased | 83.55 | 61.48 | 22 | 1905 | 10541 | 110576831 |
| Overweight | 78.64 | 61.48 | 19 | 1908 | 6445 | 110580927 |
| Fibrosis | 75.48 | 61.48 | 19 | 1908 | 7623 | 110579749 |
| Hepatic steatosis | 70.87 | 61.48 | 28 | 1899 | 48803 | 110538569 |
| Bundle branch block left | 65.64 | 61.48 | 19 | 1908 | 12869 | 110574503 |
| Nephropathy | 64.81 | 61.48 | 19 | 1908 | 13448 | 110573924 |
| Arthritis | 62.75 | 61.48 | 38 | 1889 | 167548 | 110419824 |
| Dyslipidaemia | 61.62 | 61.48 | 19 | 1908 | 15946 | 110571426 |
| Bone density decreased | 61.53 | 61.48 | 19 | 1908 | 16023 | 110571349 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | M05BA01 | MUSCULO-SKELETAL SYSTEM DRUGS FOR TREATMENT OF BONE DISEASES DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION Bisphosphonates |
| ATC | M05BB01 | MUSCULO-SKELETAL SYSTEM DRUGS FOR TREATMENT OF BONE DISEASES DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION Bisphosphonates, combinations |
| FDA CS | M0006519 | Diphosphonates |
| FDA EPC | N0000175579 | Bisphosphonate |
| MeSH PA | D050071 | Bone Density Conservation Agents |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:38161 | chelator |
| CHEBI has role | CHEBI:50646 | bone density conservation agent |
Related Drugs by ATC class:
M05BA Bisphosphonates 7 drugs
M05BB Bisphosphonates, combinations 6 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Osteitis deformans | indication | 2089002 | DOID:5408 |
| Humoral hypercalcemia of malignancy | indication | 47709007 | |
| Heterotopic ossification | indication | 128491006 | |
| Prevention of Glucocorticoid-Induced Osteoporosis | off-label use | ||
| Gastritis | contraindication | 4556007 | DOID:4029 |
| Hypocalcemia | contraindication | 5291005 | |
| Peptic ulcer | contraindication | 13200003 | DOID:750 |
| Esophagitis | contraindication | 16761005 | DOID:11963 |
| Hyperphosphatemia | contraindication | 20165001 | DOID:0050459 |
| Swallowing painful | contraindication | 30233002 | |
| Ulcer of esophagus | contraindication | 30811009 | |
| Vitamin D deficiency | contraindication | 34713006 | |
| Infectious disease | contraindication | 40733004 | |
| Dysphagia | contraindication | 40739000 | |
| Periodontitis | contraindication | 41565005 | DOID:824 |
| Enterocolitis | contraindication | 43752006 | |
| Achalasia of esophagus | contraindication | 45564002 | DOID:9164 |
| Stricture of esophagus | contraindication | 63305008 | |
| Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
| Duodenitis | contraindication | 72007001 | DOID:8643 |
| Heart failure | contraindication | 84114007 | DOID:6000 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Fracture of bone | contraindication | 125605004 | |
| Asthma | contraindication | 195967001 | DOID:2841 |
| Esophageal dysmotility | contraindication | 266434009 | DOID:9192 |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Primary malignant neoplasm | contraindication | 372087000 | |
| Aseptic necrosis of bone of jaw | contraindication | 441809006 | |
| Invasive Dental Procedure | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 1.29 | acidic |
| pKa2 | 5.36 | acidic |
| pKa3 | 6.35 | acidic |
| pKa4 | 10.42 | acidic |
| pKa5 | 12.86 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Type IV secretion-like conjugative transfer relaxase protein TraI | Enzyme | Ki | 8.52 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| N0000007216 | NUI |
| D00314 | KEGG_DRUG |
| 7414-83-7 | SECONDARY_CAS_RN |
| 4018878 | VANDF |
| 4019753 | VANDF |
| C0015121 | UMLSCUI |
| CHEBI:4907 | CHEBI |
| 911 | PDB_CHEM_ID |
| CHEMBL871 | ChEMBL_ID |
| DB01077 | DRUGBANK_ID |
| CHEMBL1201042 | ChEMBL_ID |
| D012968 | MESH_DESCRIPTOR_UI |
| 3305 | PUBCHEM_CID |
| 7184 | IUPHAR_LIGAND_ID |
| 2758 | INN_ID |
| M2F465ROXU | UNII |
| 1356715 | RXNORM |
| 4706 | MMSL |
| 81273 | MMSL |
| d00599 | MMSL |
| 002143 | NDDF |
| 004883 | NDDF |
| 372908005 | SNOMEDCT_US |
| 387581008 | SNOMEDCT_US |
| 420702005 | SNOMEDCT_US |
| 96284009 | SNOMEDCT_US |
Pharmaceutical products:
None